Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chung, M. H.
Right arrow Articles by Morton, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chung, M. H.
Right arrow Articles by Morton, D. L.
Related Collections
Right arrow Prognostic factors
Annals of Surgical Oncology 9:120-126 (2002)
© 2002 Society of Surgical Oncology

ORIGINAL ARTICLES

Serum TA90 Immune Complex Assay Can Predict Outcome After Resection of Thick (>=4 mm) Primary Melanoma and Sentinel Lymphadenectomy

Mathew H. Chung, MD, Rishab K. Gupta, PhD, Richard Essner, MD, Wei Ye, MS, Reynold Yee, BS and Donald L. Morton, MD, FACS

From the Roy E. Coats Research Laboratories, John Wayne Cancer Institute, Saint John’s Health Center, Santa Monica, California.

Correspondence: Address correspondence and reprint requests to: Donald Morton, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd., Santa Monica, CA 90404; Fax: 310-582-7185; E-mail: mortond{at}jwci.org

Background: We hypothesized that the postoperative serum level of TA90-IC, an immune complex of a 90-kDa tumor-associated antigen and its antibody, might have a significant correlation with recurrence and survival in patients with thick primary melanomas.

Methods: We used our prospective melanoma database to identify all patients who underwent wide local excision and sentinel lymphadenectomy for primary melanomas >=4 mm and from whom sera had been collected and cryopreserved within 6 months after surgery. These sera were analyzed in a blinded fashion for TA90-IC status by using our double-determinant enzyme-linked immunosorbent assay. Results were correlated with disease-free survival (DFS) and overall survival (OS). Standard prognostic factors for melanoma were then compared with TA90-IC status for the prediction of DFS and OS.

Results: The sensitivity and specificity of the TA90-IC assay for predicting recurrence were 70% and 85%, respectively. Five-year DFS and OS rates were higher for the TA90-IC-negative group than the positive group. The differences in DFS and OS between the TA90-IC-negative and -positive groups were significant. At a median follow-up of 25 months, multivariate analysis identified postoperative TA90-IC status and sex as significant predictors of DFS. TA90-IC status was the only independent prognostic factor with multivariate analysis.

Conclusions: TA90-IC status after resection of thick primary melanoma accurately predicts outcome. A positive postoperative TA90-IC level might affect a decision regarding adjuvant therapy, regardless of regional nodal status.

Key Words: TA90 immune complex • Tumor-associated antigen • Immune assay • Primary melanoma




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
C. Caraco, E. Celentano, S. Lastoria, G. Botti, P. A. Ascierto, and N. Mozzillo
Sentinel Lymph Node Biopsy Does not Change Melanoma-Specific Survival Among Patients with Breslow Thickness Greater than Four Millimeters
Ann. Surg. Oncol., March 1, 2004; 11(3_suppl): 198S - 202S.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. M. McMasters
Predicting Survival in Melanoma
Ann. Surg. Oncol., March 1, 2002; 9(2): 113 - 114.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society of Surgical Oncology.